FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560558701> ?p ?o ?g. }

• W2560558701 endingPage "1184" @default.
• W2560558701 startingPage "1176" @default.
• W2560558701 abstract "PurposeTo investigate the effect of the addition of bone morphogenetic protein 2 (BMP-2) to leukocyte-rich and platelet-rich fibrin (L-PRF) on the treatment of medication-related osteonecrosis of the jaws (MRONJ), this study compared the healing outcome of combined use of BMP-2 and L-PRF with single use of L-PRF.Patients and MethodsOf 55 patients who were diagnosed with MRONJ, 25 were treated with L-PRF alone and 30 were treated with L-PRF and recombinant human BMP-2. For each patient, surgical sites were evaluated postoperatively at 4 and 16 weeks. Associations between the treatment method and the resolution of MRONJ were analyzed with the adjustment of patient-specific factors that may influence the treatment outcome.ResultsAt 4 and 16 weeks postoperatively, patients with MRONJ who were treated with both L-PRF and BMP-2 showed favorable outcomes with complete resolution of the lesions, which was statistically significant compared with that of the therapy using L-PRF alone (P = .028). Therefore, the additional use of BMP-2 considerably improved MRONJ healing. Among patient-specific factors, the existence of a bacterial colony in the biopsy specimen was a significant factor that negatively affected disease resolution (P = .017).ConclusionsThe combined use of BMP-2 and L-PRF leads to the early resolution of MRONJ; thus patients who need to continue antiresorptive therapy may benefit from the combined regimen. To investigate the effect of the addition of bone morphogenetic protein 2 (BMP-2) to leukocyte-rich and platelet-rich fibrin (L-PRF) on the treatment of medication-related osteonecrosis of the jaws (MRONJ), this study compared the healing outcome of combined use of BMP-2 and L-PRF with single use of L-PRF. Of 55 patients who were diagnosed with MRONJ, 25 were treated with L-PRF alone and 30 were treated with L-PRF and recombinant human BMP-2. For each patient, surgical sites were evaluated postoperatively at 4 and 16 weeks. Associations between the treatment method and the resolution of MRONJ were analyzed with the adjustment of patient-specific factors that may influence the treatment outcome. At 4 and 16 weeks postoperatively, patients with MRONJ who were treated with both L-PRF and BMP-2 showed favorable outcomes with complete resolution of the lesions, which was statistically significant compared with that of the therapy using L-PRF alone (P = .028). Therefore, the additional use of BMP-2 considerably improved MRONJ healing. Among patient-specific factors, the existence of a bacterial colony in the biopsy specimen was a significant factor that negatively affected disease resolution (P = .017). The combined use of BMP-2 and L-PRF leads to the early resolution of MRONJ; thus patients who need to continue antiresorptive therapy may benefit from the combined regimen." @default.
• W2560558701 created "2016-12-16" @default.
• W2560558701 creator A5033943394 @default.
• W2560558701 creator A5047445678 @default.
• W2560558701 creator A5084669649 @default.
• W2560558701 date "2017-06-01" @default.
• W2560558701 modified "2023-10-15" @default.
• W2560558701 title "Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?" @default.
• W2560558701 cites W1597191961 @default.
• W2560558701 cites W1965303330 @default.
• W2560558701 cites W1975068146 @default.
• W2560558701 cites W1982590588 @default.
• W2560558701 cites W1994252442 @default.
• W2560558701 cites W1996176602 @default.
• W2560558701 cites W1999835833 @default.
• W2560558701 cites W2001165408 @default.
• W2560558701 cites W2008203305 @default.
• W2560558701 cites W2012985069 @default.
• W2560558701 cites W2013567846 @default.
• W2560558701 cites W2030322516 @default.
• W2560558701 cites W2049768135 @default.
• W2560558701 cites W2050658582 @default.
• W2560558701 cites W2051129327 @default.
• W2560558701 cites W2056637909 @default.
• W2560558701 cites W2058273933 @default.
• W2560558701 cites W2062366350 @default.
• W2560558701 cites W2064413596 @default.
• W2560558701 cites W2074990666 @default.
• W2560558701 cites W2080581995 @default.
• W2560558701 cites W2084865918 @default.
• W2560558701 cites W2107208293 @default.
• W2560558701 cites W2114783134 @default.
• W2560558701 cites W2120642348 @default.
• W2560558701 cites W2126164238 @default.
• W2560558701 cites W2130135377 @default.
• W2560558701 cites W2134384456 @default.
• W2560558701 cites W2139615600 @default.
• W2560558701 cites W2144860907 @default.
• W2560558701 cites W2166212566 @default.
• W2560558701 cites W2330436103 @default.
• W2560558701 cites W4244095134 @default.
• W2560558701 doi "https://doi.org/10.1016/j.joms.2016.12.005" @default.
• W2560558701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28042979" @default.
• W2560558701 hasPublicationYear "2017" @default.
• W2560558701 type Work @default.
• W2560558701 sameAs 2560558701 @default.
• W2560558701 citedByCount "57" @default.
• W2560558701 countsByYear W25605587012017 @default.
• W2560558701 countsByYear W25605587012018 @default.
• W2560558701 countsByYear W25605587012019 @default.
• W2560558701 countsByYear W25605587012020 @default.
• W2560558701 countsByYear W25605587012021 @default.
• W2560558701 countsByYear W25605587012022 @default.
• W2560558701 countsByYear W25605587012023 @default.
• W2560558701 crossrefType "journal-article" @default.
• W2560558701 hasAuthorship W2560558701A5033943394 @default.
• W2560558701 hasAuthorship W2560558701A5047445678 @default.
• W2560558701 hasAuthorship W2560558701A5084669649 @default.
• W2560558701 hasBestOaLocation W25605587011 @default.
• W2560558701 hasConcept C104317684 @default.
• W2560558701 hasConcept C126322002 @default.
• W2560558701 hasConcept C141071460 @default.
• W2560558701 hasConcept C185592680 @default.
• W2560558701 hasConcept C199343813 @default.
• W2560558701 hasConcept C202751555 @default.
• W2560558701 hasConcept C203014093 @default.
• W2560558701 hasConcept C2776541429 @default.
• W2560558701 hasConcept C2777251235 @default.
• W2560558701 hasConcept C2777556957 @default.
• W2560558701 hasConcept C2777560349 @default.
• W2560558701 hasConcept C2781413609 @default.
• W2560558701 hasConcept C30352789 @default.
• W2560558701 hasConcept C31507581 @default.
• W2560558701 hasConcept C54173615 @default.
• W2560558701 hasConcept C55493867 @default.
• W2560558701 hasConcept C71924100 @default.
• W2560558701 hasConcept C8337478 @default.
• W2560558701 hasConceptScore W2560558701C104317684 @default.
• W2560558701 hasConceptScore W2560558701C126322002 @default.
• W2560558701 hasConceptScore W2560558701C141071460 @default.
• W2560558701 hasConceptScore W2560558701C185592680 @default.
• W2560558701 hasConceptScore W2560558701C199343813 @default.
• W2560558701 hasConceptScore W2560558701C202751555 @default.
• W2560558701 hasConceptScore W2560558701C203014093 @default.
• W2560558701 hasConceptScore W2560558701C2776541429 @default.
• W2560558701 hasConceptScore W2560558701C2777251235 @default.
• W2560558701 hasConceptScore W2560558701C2777556957 @default.
• W2560558701 hasConceptScore W2560558701C2777560349 @default.
• W2560558701 hasConceptScore W2560558701C2781413609 @default.
• W2560558701 hasConceptScore W2560558701C30352789 @default.
• W2560558701 hasConceptScore W2560558701C31507581 @default.
• W2560558701 hasConceptScore W2560558701C54173615 @default.
• W2560558701 hasConceptScore W2560558701C55493867 @default.
• W2560558701 hasConceptScore W2560558701C71924100 @default.
• W2560558701 hasConceptScore W2560558701C8337478 @default.
• W2560558701 hasIssue "6" @default.
• W2560558701 hasLocation W25605587011 @default.
• W2560558701 hasLocation W25605587012 @default.

• next